The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Effects of olanzapine combined with sodium valproate on symptoms, inflammatory markers, and cognitive function in patients with bipolar disorder
Open accessAbstract
Bipolar disorder (BD) is a chronic mental health condition characterized by alternating manic and depressive episodes that significantly impact mood and cognitive function. Recent research has linked BD to neuroinflammation. Despite the availability of antipsychotics and mood stabilizers as standard treatments, their efficacy and side effects can vary, underscoring the need for more effective therapeutic strategies. This study aims to evaluate the combined effects of olanzapine and sodium valproate on clinical symptoms and inflammatory markers in patients with BD. A total of 80 BD patients from the Fifth People’s Hospital of Jiujiang, treated between April 2022 and April 2024, were enrolled in the study. They were divided into 2 groups: the control group, which received olanzapine monotherapy, and the observation group, which received a combination of olanzapine and sodium valproate. After 8 weeks of treatment, clinical efficacy was assessed using the Bech-Rafaelsen Mania scale and the Hamilton depression scale. Serum inflammatory markers, including interleukin-1, interleukin-10, and tumor necrosis factor-alpha, were measured along with neuroendocrine function indicators (thyroid hormone, cortisol, thyroid-stimulating hormone, and adrenocorticotropic hormone). Cognitive function was evaluated using computerized assessments, and adverse events were monitored and recorded. The observation group exhibited significantly lower Bech-Rafaelsen Mania scale and Hamilton depression scale scores, as well as reduced interleukin-1 and tumor necrosis factor-alpha levels compared to the control group. Both groups showed decreased levels of serum thyroid hormone, cortisol, and adrenocorticotropic hormone, along with increased thyroid-stimulating hormone levels after treatment, with more pronounced changes observed in the observation group ( P < .01). Additionally, cognitive function scores were significantly higher in the observation group ( P < .05), and the incidence of adverse events was lower (15.00% vs 22.50%, χ² = 0.38, P < .01). The combination of olanzapine and sodium valproate leads to significant improvements in clinical symptoms, reduces inflammatory markers, enhances cognitive function, and demonstrates greater safety compared to olanzapine monotherapy. This combination therapy offers a promising treatment approach for managing BD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In a study conducted on patients with BD, Wang et al. (2025) reported lower IL-1 and TNF-α levels in patients treated with a combination of olanzapine and VPA than in those receiving olanzapine monotherapy (Wang et al. 2025).”
From Mood stabilizers and systemic inflammatory burden in euthymic patients with bipolar disorder: a comparative study of lithium and valproate (2026) · doi:10.1007/s00213-026-07111-x · cites this paper as Wang et al. 2025
In the citing paper
“Indeed, recent evidence has demonstrated that VPA not only reduces the inflammatory burden in patients with BD but may also be associated with improvements in cognitive functioning (Wang et al. 2025).”
From Mood stabilizers and systemic inflammatory burden in euthymic patients with bipolar disorder: a comparative study of lithium and valproate (2026) · doi:10.1007/s00213-026-07111-x · cites this paper as Wang et al. 2025
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31135-3 · Cited by 1,753
Severity classification on the Hamilton depression rating scale
Zimmerman, M., Martinez, J. H., Young, D., Chelminski, I., & Dalrymple, K. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.04.028 · Cited by 1,199
Pillinger, T., McCutcheon, R. A., Vano, L., Mizuno, Y., Arumuham, A., Hindley, G., Beck, K., Natesan, S., Efthimiou, O., Cipriani, A., et al. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30416-x · Cited by 1,090
Hirschfeld, R. M. A., Lewis, L., & Vornik, L. A. (2003) · PubMed · Cited by 943
Hirschfeld, R. M. A., Lewis, L., & Vornik, L. A. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0209 · Cited by 922
Cipriani, A., Barbui, C., Salanti, G., Rendell, J., Brown, R., Stockton, S., Purgato, M., Spineli, L. M., Goodwin, G. M., & Geddes, J. R. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60873-8 · Cited by 631
Bech, Bolwig, Kramp, P., & Rafaelsen, O. J. (1979) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1979.tb04484.x · Cited by 405
Therapeutic potential of mood stabilizers lithium and valproic acid:Beyond bipolar disorder
Chiu, C.-T., Wang, Z., Hunsberger, J. G., & Chuang, D.-M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005512 · Cited by 404
Research works printed but not linked: 1
- Connolly, 2011, The clinical management of bipolar disorder: a review of evidence-based guidelines., Prim Care Companion CNS Disord, 13, PCC.10r01097
Cited by
Fan, X., Shi, X., Deng, F., Cai, Y., Liu, Y., Zhao, Y. W., Wang, H., Jiwu, L., & Pan, J. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07384-0 · Cited by 1
“Furthermore, sodium valproate and certain second-generation antipsychotics may also influence thyroid hormone metabolism [43].”
Wang, F., Lai, X., Zhou, S., Lin, J. I. N. Y. I., Xin, H., Tao, Z., Wang, X., Zhang, S., LIU, Z., Tan, H., et al. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s598447 · Cited by 1
“…cognitive function, reduced inflammatory biomarkers, and lowered the incidence of adverse reactions compared to olanzapine monotherapy in patients with BD. 8 These findings suggest that the combination therapy is not only effective, but also offer superior therapeutic profile for BD patients.”
Self-citation(2026) · doi:10.1007/s00213-026-07111-x
Gao, Y., Deng, Y., Yang, C., & Zhang, J. V. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-07892-7
“Bipolar disorder (BD), a chronic mental disorder, is featured by a complex clinical presentation, with its core feature being the recurrent and alternating episodes of mania/hypomania and depression [1].”
Zhou, F., Cai, X., & Wu, C. (2026) · Biomedical Chromatography · doi:10.1002/bmc.70536
Metadata
- Authors
- Wang, X., Ye, F., Zhang, Z., Zhang, Q., & Li, G.
- Affiliations
- Department of Psychological Assessment Room, Jiujiang Fifth People’s Hospital, Jiujiang, Jiangxi Province, China
- Jiujiang First People's Hospital (CN)
- Department of Psychiatry, The Fifth People’s Hospital of Jiujiang City, Jiujiang, Jiangxi Province, China
- Corresponding author
- Li, Guanhua
- Venue
- Medicine
- Published
- 2025-06-27
- Volume
- 104
- Issue
- 26
- Pages
- e42803
- ISSN
- 0025-7974 (ISSN-L)
- 1536-5964
- PMC
- PMC12212825
- OpenAlex
- W4411789199
- Cited by
- 5
- References
- 35
- Citations by year
- 2026: 4 · 2025: 1
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- bipolar disorder, olanzapine, valproic acid, combination therapy, neuroinflammation, inflammatory markers, interleukin-1, IL-10, TNF-α, thyroid function, cortisol, cognitive function, mania, depression, adverse events
- MeSH terms
- Olanzapine, Adult, Bipolar Disorder, Cognition, Drug Therapy, Combination, Female, Humans, Inflammation, Male, Middle Aged, Psychiatric Status Rating Scales, Antipsychotic Agents, Valproic Acid, Biomarkers, Treatment Outcome, Antimanic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of olanzapine combined with sodium valproate on symptoms, inflammatory markers, and cognitive function in patients with bipolar disorder. https://app.cochat.ai/papers/10.1097/md.0000000000042803
- The paper
- Wang, X., Ye, F., Zhang, Z., Zhang, Q., & Li, G. (2025). Effects of olanzapine combined with sodium valproate on symptoms, inflammatory markers, and cognitive function in patients with bipolar disorder. Medicine. https://doi.org/10.1097/md.0000000000042803
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.